Aberrant promoter CpG methylation and its translational applications in breast cancer

Breast cancer is a complex disease driven by multiple factors including both genetic and epigenetic alterations. Recent studies revealed that abnormal gene expression induced by epigenetic changes, including aberrant promoter methylation and histone modification, plays a critical role in human breast Carcinogenesis. Silencing of tumor suppressor genes (TSGs) by promoter CpG methylation facilitates cells growth and survival advantages and further results in tumor initiation and progression, thus directly contributing to breast tumorigenesis. Usually, aberrant promoter methylation of TSGs, which can be reversed by pharmacological reagents, occurs at the early stage of tumorigenesis and therefore may serve as a potential tumor marker for early diagnosis and therapeutic targeting of breast cancer. In this review, we summarize the epigenetic changes of multiple TSGs involved in breast pathogenesis and their potential clinical applications as tumor markers for early detection and treatment of breast cancer.

• Publication year

  2013

• Venue

  Chinese journal of cancer

• Publication date

  2013-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.5732/cjc.011.10344PMID 22059908PMCID 3845590
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors

  2011cited by this paper
• Integrated Analysis of Gene Expression, CpG Island Methylation, and Gene Copy Number in Breast Cancer Cells by Deep Sequencing

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Functional characterization of Trip10 in cancer cell growth and survival

  2011cited by this paper
• Hypermethylation of Tumor Suppressor Genes Involved in Critical Regulatory Pathways for Developing a Blood-Based Test in Breast Cancer

  2011cited by this paper
• Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer

  2010cited by this paper
• Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells

  2010cited by this paper
• Epigenetic change in e-cardherin and COX-2 to predict chronic periodontitis

  2010cited by this paper
• Gene Methylation in Breast Ductal Fluid from BRCA1 and BRCA2 Mutation Carriers

  2010cited by this paper
• Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer.

  2010cited by this paper
• Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells

  2010cited by this paper
• Myc interacts with Max and Miz1 to repress C/EBPδ promoter activity and gene expression

  2010cited by this paper
• Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients

  2010cited by this paper
• Identification of 5 novel genes methylated in breast and other epithelial cancers

  2010cited by this paper
• DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response

  2010cited by this paper
• PLCD1 is a functional tumor suppressor inducing G2/M arrest and frequently methylated in breast cancer

  2010cited by this paper
• Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer

  2010cited by this paper
• Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells

  2010cited by this paper
• Epigenetic Signatures in Breast Cancer: Clinical Perspective

  2010cited by this paper
• Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns

  2010cited by this paper
• Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors

  2010cited by this paper
• Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer

  2010cited by this paper
• Sulforaphane Causes Epigenetic Repression of hTERT Expression in Human Breast Cancer Cell Lines

  2010cited by this paper
• Clinical Significance of Epigenetic Inactivation of hMLH1 and BRCA1 in Tunisian Patients with Invasive Breast Carcinoma

  2009cited by this paper
• Deregulation of 2 Potassium Channels in Pancreas Adenocarcinomas: Implication of KV1.3 Gene Promoter Methylation

  2009cited by this paper
• CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis.

  2009cited by this paper
• Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors

  2009cited by this paper
• The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer

  2009cited by this paper
• Promoter methylation and the detection of breast cancer

  2009cited by this paper
• CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells

  2009cited by this paper
• Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer

  2009cited by this paper
• Phase I Study of MG 98 , an OligonucleotideAntisense Inhibitor of Human DNAMethyltransferase 1 , Given as a 7-Day Infusion in Patients with Advanced SolidTumors

  2009cited by this paper
• Optimizing the yield and utility of circulating cell-free DNA from plasma and serum.

  2009cited by this paper
• Methylation‐associated silencing of SFRP1 with an 8p11‐12 amplification inhibits canonical and non‐canonical WNT pathways in breast cancers

  2009cited by this paper
• Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer

  2009cited by this paper
• The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer

  2009cited by this paper
• Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.

  2009cited by this paper
• Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer

  2009cited by this paper
• Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer

  2008cited by this paper
• Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors

  2008cited by this paper
• Methylation of WTH3, a possible drug resistant gene, inhibits p53 regulated expression

  2008cited by this paper
• Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis.

  2008cited by this paper
• The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.

  2008cited by this paper
• OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently Epigenetic Inactivation

  2008cited by this paper
• Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer.

  2008cited by this paper
• Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy

  2008cited by this paper
• Quantitative detection of methylated ESR1 and 14-3-3-σ gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy

  2008cited by this paper
• A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia

  2008cited by this paper
• Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.

  2008cited by this paper
• Epigenetic disruption of interferon-γ response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas

  2008cited by this paper
• Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours

  2008cited by this paper
• Oxytocin: bringing magic into nipple aspiration.

  2007cited by this paper
• Cancer epigenomics: DNA methylomes and histone-modification maps

  2007cited by this paper
• Methylation of the BIN1 gene promoter CpG island associated with breast and prostate cancer

  2007cited by this paper
• The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation

  2007cited by this paper
• Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.

  2007cited by this paper
• CMTM5 Exhibits Tumor Suppressor Activities and Is Frequently Silenced by Methylation in Carcinoma Cell Lines

  2007cited by this paper
• Breast cancer: origins and evolution.

  2007cited by this paper
• Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.

  2007cited by this paper
• Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.

  2007cited by this paper
• Epigenetic cancer therapy makes headway.

  2006cited by this paper
• Association of GSTP1 CpG Islands Hypermethylation with Poor Prognosis in Human Breast Cancers

  2006cited by this paper
• Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis

  2006cited by this paper
• [Breast cancer].

  2006cited by this paper
• Epstein-Barr virus (EBV) and its associated human cancers--genetics, epigenetics, pathobiology and novel therapeutics.

  2006cited by this paper
• Faculty Opinions recommendation of The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.

  2006cited by this paper
• Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid

  2006cited by this paper
• Circulating Methylated DNA: A New Generation of Tumor Markers

  2006cited by this paper
• Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer.

  2006cited by this paper
• Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression.

  2006cited by this paper
• Identification of 20 genes aberrantly methylated in human breast cancers

  2005cited by this paper
• [Epigenetic inactivation of the WNT antagonist SFRP1 in breast cancer].

  2005cited by this paper
• p16INK4a promoter methylation and protein expression in breast fibroadenoma and carcinoma

  2005cited by this paper
• Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer

  2005cited by this paper
• Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases.

  2005cited by this paper
• P-Cadherin Overexpression Is an Indicator of Clinical Outcome in Invasive Breast Carcinomas and Is Associated with CDH3 Promoter Hypomethylation

  2005cited by this paper
• Role of the Ras-association domain family 1 tumor suppressor gene in human cancers.

  2005cited by this paper
• High frequency of promoter hypermethylation of RASSF1A in tumorous and non‐tumourous tissue of breast cancer

  2005cited by this paper
• Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2

  2005cited by this paper
• Promoter methylation of the PTEN gene is a common molecular change in breast cancer

  2004cited by this paper
• Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer

  2004cited by this paper
• MDR1 Promoter Hypermethylation in MCF-7 Human Breast Cancer Cells: Changes in Chromatin Structure Induced by Treatment with 5-Aza-Cytidine

  2004cited by this paper
• Tumor Suppressor Gene Promoter Hypermethylation in Serum of Breast Cancer Patients

  2004cited by this paper
• The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.

  2004cited by this paper
• Evaluation of antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines

  2004cited by this paper
• Epigenetic regulation of protein phosphatase 2A (PP2A), Lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells

  2004cited by this paper
• The ATM gene is a target for epigenetic silencing in locally advanced breast cancer

  2004cited by this paper
• DNA methylation of RASSF1A, HIN‐1, RAR‐β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma

  2003cited by this paper
• Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.

  2003cited by this paper
• Specific Inhibition of DNMT1 by Antisense Oligonucleotides Induces Re-expression of Estrogen Receptor a (ER) in ER-negative Human Breast Cancer Cell Lines

  2003cited by this paper
• DNA methylation in serum of breast cancer patients: an independent prognostic marker.

  2003cited by this paper
• Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer.

  2002cited by this paper
• DNA methylation and breast carcinogenesis

  2002cited by this paper
• Quantitative assessment of promoter hypermethylation during breast cancer development.

  2002cited by this paper
• Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer.

  2002cited by this paper
• Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.

  2001cited by this paper
• HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells

  2001cited by this paper
• Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.

  2001cited by this paper
• Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer.

  2001cited by this paper
• Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.

  2001cited by this paper

• A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation.

  2024cites this paper
• Epigenetic identification of LTBP4 as a putative tumor suppressor in breast cancer.

  2024cites this paper
• Selective Estrogen Receptor Modulators’ (SERMs) Influence on TET3 Expression in Breast Cancer Cell Lines with Distinct Biological Subtypes

  2024cites this paper
• Zinc finger and SCAN domain-containing protein 18 is a potential DNA methylation-modified tumor suppressor and biomarker in breast cancer

  2023cites this paper
• Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approaches.

  2023cites this paper
• Expression of Esophageal Cancer-Related Gene 4: A Candidate Tumor Suppressor Gene, Regulated by Methylation Level in Laryngeal Malignant Tumor

  2023cites this paper
• Melatonin: A Potential Regulator of DNA Methylation

  2023cites this paper
• Detection of aberrantly methylated tumor suppressor genes in breast cancer patients as a potential diagnostic biomarker

  2021cites this paper
• Epigenetic identification of mitogen-activated protein kinase 10 as a functional tumor suppressor and clinical significance for hepatocellular carcinoma

  2021cites this paper
• Pterostilbene Changes Epigenetic Marks at Enhancer Regions of Oncogenes in Breast Cancer Cells

  2021cites this paper
• Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival

  2021cites this paper
• Transcriptional Factor Yin Yang 1 Promotes the Stemness of Breast Cancer Cells by Suppressing miR-873-5p Transcriptional Activity

  2020cites this paper
• Integrative Bioinformatics Analysis Identified Hub Genes in Association with Development of Lung Adenocarcinoma

  2020cites this paper
• Rhus coriaria L. (Sumac) Demonstrates Oncostatic Activity in the Therapeutic and Preventive Model of Breast Carcinoma

  2020cites this paper
• Correlation of MSH2 exonic deletions and protein downregulation with breast cancer biomarkers and outcome in Pakistani women/patients

  2020cites this paper
• Epigenetic and Breast Cancer Therapy: Promising Diagnostic and Therapeutic Applications.

  2020cites this paper
• Aberrantly Methylated cfDNA in Body Fluids as a Promising Diagnostic Tool for Early Detection of Breast Cancer.

  2020cites this paper
• Expressional analysis of MLH1 and MSH2 in breast cancer.

  2019cites this paper
• Consequences of Artificial Light at Night: The Linkage between Chasing Darkness Away and Epigenetic Modifications

  2019cites this paper
• Artificial Light Pollution at Night: A Risk for Normal Circadian Rhythm and Physiological Functions in Humans

  2019cites this paper
• Epigenetic identification of ADCY4 as a biomarker for breast cancer: an integrated analysis of adenylate cyclases.

  2019cites this paper
• Paclitaxel Response Can Be Predicted With Interpretable Multi-Variate Classifiers Exploiting DNA-Methylation and miRNA Data

  2019cites this paper
• Homeobox protein MSX1 inhibits the growth and metastasis of breast cancer cells and is frequently silenced by promoter methylation.

  2018cites this paper
• Cucurbitacin B Induces Hypermethylation of Oncogenes in Breast Cancer Cells

  2018cites this paper
• Artificial Light at Night of Different Spectral Compositions Differentially Affects Tumor Growth in Mice: Interaction With Melatonin and Epigenetic Pathways

  2018cites this paper
• Epigenetic silencing of RNF144A expression in breast cancer cells through promoter hypermethylation and MBD4

  2018cites this paper
• The tumor suppressor interferon regulatory factor 8 inhibits β-catenin signaling in breast cancers, but is frequently silenced by promoter methylation

  2017cites this paper
• the epigenetics in breast cancer review of its pathogenic implications and projection in the clinical area

  2017cites this paper
• Breast Cancer Epigenetics: Modification by Genistein

  2017cites this paper
• Artificial light-at-night – a novel lifestyle risk factor for metabolic disorder and cancer morbidity

  2017cites this paper
• DACT2 silencing by promoter CpG methylation disrupts its regulation of epithelial-to-mesenchymal transition and cytoskeleton reorganization in breast cancer cells

  2016cites this paper
• Methylation Analysis of BRCA1 and APC in Breast Cancer and It's Relationship to Clinicopathological Features.

  2016cites this paper
• Protocadherin 17 functions as a tumor suppressor suppressing Wnt/β-catenin signaling and cell metastasis and is frequently methylated in breast cancer

  2016cites this paper
• Methylation Landscape of Human Breast Cancer Cells in Response to Dietary Compound Resveratrol

  2016cites this paper
• Original article: DNA METHYLATION ASSESSMENT AS A PROGNOSTIC FACTOR IN INVASIVE BREAST CANCER USING METHYLATION-SPECIFIC MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION

  2016cites this paper
• DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification

  2016cites this paper
• Elucidation of Mechanisms Underlying Metastatic Melanoma Immune Escape via Suppression of Major Histocompatibility Complex (MHC) II through Dysregulation of the JAK/STAT Pathway

  2015cites this paper
• Epigenetics Territory and Cancer

  2015cites this paper
• LED light between Nobel Prize and cancer risk factor

  2015cites this paper
• Chapter 17 – Nasopharyngeal Cancer

  2015cites this paper
• Epigenetic of Retinoic Acid Receptor β2 Gene in Breast Cancer

  2015cites this paper
• Melatonin Functioning Through DNA Methylation to Constricts Breast Cancer Growth Accelerated by Blue LED Light-At-Night in 4T1 Tumor-Bearing Mice Journal of Cancer Biology and Therapeutics

  2015cites this paper
• DNA Methyltransferases and Methylation of CpG islands

  2015cites this paper
• Epigallocatechin 3-gallate applications on HT-29 and MCF-7 cell lines andevaluation of tumor suppressor gene methylation

  2015cites this paper
• Artificial light at night: melatonin as a mediator between the environment and epigenome

  2015cites this paper
• The Role of Methylation in Breast Cancer Susceptibility and Treatment.

  2015cites this paper
• One-Carbon Metabolism Nutrients and Epigenetics: A Mechanistic Link Between Aberrant One-Carbon Metabolism and Cancer Risk?

  2014cites this paper
• E4BP4 is a repressor of epigenetically regulated SOSTDC1 expression in breast cancer cells

  2014cites this paper
• Molecular mechanisms and physiology of disease

  2014cites this paper
• Nuclear-encoded mitochondrial MTO1 and MRPL41 are regulated in an opposite epigenetic mode based on estrogen receptor status in breast cancer

  2013cites this paper
• Changes in Gene Methylation Following Chemotherapy in Breast Cancer Cell Lines

  2013cites this paper
• Male breast cancer: genetics, epigenetics, and ethical aspects.

  2013cites this paper
• Epigenetic Changes in Carcinogenesis of Gallbladder

  2013cites this paper
• Implication of the Strand-Specific Imprinting and Segregation Model: Integrating in utero Hormone Exposure, Stem Cell and Lateral Asymmetry Hypotheses in Breast Cancer Aetiology

  2013cites this paper
• Identification of Hypermethylation in Hepatocyte Cell Adhesion Molecule Gene Promoter Region in Bladder Carcinoma

  2013cites this paper
• DACT1, an antagonist to Wnt/β-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer

  2013cites this paper